Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Compugen Ltd.NASDAQ: CGEN

Other Non-Cash Items · Q4 FY2025 · quarter ended Dec 2025

Other non-cash items of -$56.85M in Q4 FY2025

Q4 FY2025 other non-cash items was -$56.85M. Trailing-twelve-month other non-cash items was -$35.34M. Over 3 fiscal years it compounded at +31.2% a year.

Context

  • Other non-cash items amounted to 1.6% of revenue in FY2025, down 4.6 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near -$56.85M or moves back toward the trailing-twelve-month quarterly average of -$8.84M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$56.85M-914.5% QoQ
Last fiscal yearDec 2025
$1.16M+167.5% YoY
LTMDec 2025
-$35.34M— YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+167.5%——
3-year CAGR+31.2%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
1.16M USD
Year-over-year change
+167.5%

Other Non-Cash Items vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Other non-cash items amounts to 48.6% of revenue for CGEN, versus a peer median of 37.5%.
CGEN Competitors
Other Non-Cash Items for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Dec 2025$35.34M USD—+31.2%48.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$8.26M USD+157.5%+340.4%463.2%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$6.17M USD———
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$4.66M USD-92.7%-11.0%26.5%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.3M CHF+257.9%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.19M USD+136.6%+854.5%37.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$1.13M USD-30.3%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$804K USD+38.9%—153.1%
IPHAInnate Pharma S.A.FY2025€630.52K EUR-75.0%—22.6%
Peer median (excluding CGEN) —+38.9%+340.4%37.5%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Depreciation & Amortization461K482K476K486K475K
Deferred Income Tax00000
Stock-Based Compensation4.28M4.33M3.55M3.02M0
Change in Working Capital6.82M(5.55M)(20.71M)62.05M(5.35M)
Accounts Receivables2M3.04M(61.11M)59.93M360K
Inventory(3.37M)0000
Accounts Payables3.37M(1.6M)3.51M(4.41M)517K
Other Working Capital3.79M(7M)36.9M6.53M(6.23M)
Other Non-Cash Items(573K)515K(452K)(1.72M)1.16M
Operating Cash Flow(22.75M)(34.51M)(35.89M)49.6M31.63M
Capital Expenditures(292K)(487K)(172K)(118K)(306K)
Acquisitions (Net)3K2K001K
Purchases of Investments(129.95M)(76.9M)(53.71M)(159.75M)(96.07M)
Sales of Investments136.85M114.45M89.39M113.95M126.37M
Other Investing Activities000(329K)0
Investing Cash Flow6.62M37.06M35.51M(46.25M)30M
Debt Repayment00000
Common Stock Issued14.96M353K3.08M544K10.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.88M0010K(4K)
Financing Cash Flow16.84M353K3.08M554K10.6M
Effect of Forex Changes469K(584K)129K68K135K
Net Change in Cash704K2.91M2.83M3.97M72.37M
Free Cash Flow(23.04M)(34.99M)(36.06M)49.49M31.33M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.